ALL

(redirected from acute lymphocytic leukemia)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to acute lymphocytic leukemia: acute myeloid leukemia

ALL

The ISO 4217 currency code for Albanian Lek.

ALL

ISO 4217 code for the Albanian lek. It was introduced in 1926 and is a floating currency.
References in periodicals archive ?
Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics.
GlaxoSmithKline Pharmaceuticals Limited and Genzyme Corporation rule the present market for acute lymphocytic leukemia drugs; whereas ERYtech Pharma & Talon Therapeutic Inc are expected to capture major share of the market by 2020.
has the largest market in 2013 with a market share of approximately 55% to 60% of the Acute Lymphocytic Leukemia Therapeutics Market in G8 countries, followed by Germany and Italy.
This type of cancer can be sub-categorized into childhood acute lymphocytic leukemia and adult acute lymphocytic leukemia.
Acute lymphocytic leukemia is the most common form in children, with 1,600 new cases diagnosed a year.
Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005.
David's diagnosis of acute lymphocytic leukemia accounts for one of roughly 1,600 cases of leukemia expected among children nationwide this year, officials said.
Callisto's second drug in the clinic, L-Annamycin, is currently in a Phase I/II clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia.
But in children like David with acute lymphocytic leukemia, the five-year survival rate has increased from 53 percent to 78 percent, officials said.
Callisto's second cancer drug in the clinic, L-Annamycin, is currently in a Phase I/II clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia.
Noah Wehner, 12 years old, of Orange County was diagnosed with acute lymphocytic leukemia (ALL) when he was three and a half years old.
Full browser ?